Institute News

Institute open day: lab-grown organs, HIV vaccines, cure for cancer

The Institute's recent open day featured hands-on displays and demonstrations,  including 3-D printing of tissue-scaffolds for ear and nose replacement. Visitors chatted eagerly with scientists about their research, and heard presentations about ground-breaking work to develop new treatments for diseases including type-1 diabetes, cancer, scleroderma and hepatitis as well as HIV vaccines and artificial tissues and organs for transplantation.

Institute focus on United Arab Emirates health concerns

Professor Hans Stauss, Co-Director of UCL’s Division of Infection and Immunity, and Professor Michael Arthur, UCL President and Provost, visited the UAE to raise the profile of the Institute of Immunity and Transplantation and of UCL’s research on new treatments for diabetes, cancer, haemophilia and other diseases affecting the region. The academics met alumni and donors during their April 2014 trip, with the support of UCL’s Development and Alumni Relations team. More...


The Institute focusses on “bench to bedside” translational research to develop vaccinations, gene therapy and cell therapy to target immune-related conditions, as well as new types of transplant.  Clinical areas include:

  • cancer and leukaemia
  • chronic infections such as HIV, viral hepatitis and tuberculosis
  • auto-immune diseases including diabetes, scleroderma and inflammatory bowel disease
  • inherited immunodeficiency
  • other rare diseases such as haemophilia and amyloidosis
  • tissue and organ transplantation.
Prof Lucy Walker and HRH the Duke of York

Specific projects to improve early diagnosis and therapeutic options include:

  • Successful development of gene therapy for haemophilia B, and expanding this to other forms of haemophilia and to lysosomal storage diseases.
  • Improviding leukaemia immunotherapy through new lentiviral-vector vaccines targetting skin dendritic cells.
  • Developing new vaccination protocols to prevent viral disease in transplant patients
  • Adoptive cell therapy for leukaemia/lymphoma and viral infection
  • Innovative gene therapies for leukaemia, solid cancers and chronic infection
  • Discovering the genetic basis of certain forms of immunodeficiency and autoimmune conditions such as inflammatory bowel disease, facilitating early diagnosis and treatment
  • New biological therapies for patients with scleroderma, rheumatoid arthritis and pulmonary arterial hypertension
  • Tissue engineering and artificial organs for transplantation
  • Immune therapy for type 1 diabetes
  • Immune regulation and transplantation immunity
  • Hepatitis C virus cell-entry and antibody modulation.

Find out more about our researchers.

Page last modified on 29 jul 13 15:33